Register for our S/EIS Fund

According to the WHO, antibiotic resistance is one of the biggest threats to global health, food security, and development today. Also, a growing number of infections such as pneumonia, tuberculosis, gonorrhea, and salmonellae are becoming harder to treat as the antibiotics used to treat them become less effective.

In this ChaiTime, Aleks quizzed some of the most innovative biotech companies in the space from both Cambridge and Oxford who are one of the pioneers/leaders in this battle.

The panelists
Ken Bradley Global Head

Ken Bradley is a Global Head at Infectious Disease Discovery in Roche pharmaceutical Research and Early Development (pRED)

Paul Finn CEO of Oxford University

Paul is CEO of Oxford University Spinout, Oxford Drug Design

Ankit Mahadevia CEO of NASDAQ

Ankit is CEO of NASDAQ listed, Spero Therapeutics

Ajay Mistry CEO at Oppilotech

Ajay is CEO of AI and antibiotics discovery start-up, Oppilotech

Aleks Engel Partner at Novo Holdings (Moderator)

Alexs is Partner at Novo Holdings (Novo Seeds) and Director REPAIR Impact Fund at Novo Holdings

Register for Invitations